CEACAM5 and cancer: Although many surveillance methods (e.g., CEA, CT, and PET) have been used in clinical practice, 30−50% of CRC patients experience cancer recurrence and die from their cancer, indicating that there is an urgent need for new markers for detecting CRC recurrence.